COVID-19: ACT trials for colchicine and antithrombotic therapies.

Barco, Stefano; Schreiber, Karen

Barco, Stefano; Schreiber, Karen.

Barco S; Department of Angiology, University Hospital Zurich, 8091 Zurich, Switzerland; Center for Thrombosis and Hemostasis, Johannes Gutenberg University Mainz, Mainz, Germany. Electronic address: stefano.barco@usz.ch.
Schreiber K; Danish Hospital for Rheumatic Diseases, University of Southern Denmark, Sønderborg, Denmark; Department of Regional Health Research (IRS), University of Southern Denmark, Odense, Denmark; Thrombosis and Haemostasis, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Lancet Respir Med ; 10(12): 1106-1108, 2022 Dec.

Article in English | MEDLINE | ID: covidwho-2113984

Subject(s)

COVID-19 Drug Treatment; Humans; Colchicine/therapeutic use; Fibrinolytic Agents/therapeutic use; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Limits: Humans Language: English Journal: Lancet Respir Med Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google